Tissue Diagnostics Market by Product [Consumables (Antibodies, Kits, Reagents, Probes, and Others), Instruments (Slide-staining Systems, Scanners, Tissue-processing Systems, Histology & Hematology Stains, Cytology Stains & Bacteriology Stains, and Other Instruments)], Technology (Immunohistochemistry, In Situ Hybridization, Digital Pathology & Workflow, Special Staining, and Others), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, and Other Diseases), End User (Hospitals, Pharmaceutical Companies, Research Laboratories, Contract Research Organizations, and Other End Users): Global Market Size Estimates and Forecast (2022-2030)

The market crossed US$ 5.46 billion mark in 2022 and is expected to hit US$ 8.69 billion by 2030, recording a CAGR of 6.0 % during the forecast period. 

Rising prevalence of cancer has aided the overall market growth

According to the WHO, one-fifth of all cancers worldwide are caused by chronic infectious agents, for instance, hepatitis B virus, HIV, HPV, and Helicobacter pylori. According to GLOBACON, cancer prevailed among the 37.4 million (including 18.1 nonmelanoma skin cancer) population and accounted for 19.9 (including 9.9 nonmelanoma skin cancer) million deaths in 2020. The increase in cancer incidence can be attributed to the growing geriatric population. According to estimates from the International Agency for Research on Cancer (IARC), globally, new cancer cases are expected to grow to 27.5 million in 2022, and 16.3 million cancer deaths are expected to occur due to the growing number of total and aged population by 2040.

Within the report, the market is segmented into product, technology, disease, end user, and geography. By product, the market is further bifurcated into consumables and instruments. Consumables segment is further segmented into antibodies, kits, reagents, and probes. Instruments is segmented into slide-staining systems, scanners, tissue-processing systems, and other instruments. On the technology, the market is segmented into immunohistochemistry, in situ hybridization, digital pathology & workflow, and special staining. By disease, the market is categorized into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other diseases. Based on end user, the market is segmented into hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users. Geographically, the market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

Get more information on this report : Request Free Sample PDF

Advanced technological advancements such as MRI and X-ray evaluate features of the tissue, whereas scintigraphy, SPECT, and PET utilize radiopharmaceuticals, such as immunoradionuclides and metabolites, to assess tumor characteristics and properties. In February 2021, NCI-CONNECT launched a study across its network of medical collaborators to better understand rare brain and spine tumors. The study collects tumor tissue and comprehensive clinical data from deceased patients with rare brain and spine tumors and people that were pregnant at diagnosis or became pregnant after diagnosis of primary brain tumor. The study has primarily two components. The main focus was to study 11 rare types that were included in the NCI-CONNECT program. The concerned study is considered to be a breakthrough in tumor cases that is allowing advancements in tumor field. Such trends are expected to drive the overall tissue diagnostics market during the forecast period.

Hospitals segment in end user captured the largest share in 2022

Hospitals dominated the end-use segment in 2022, in terms of revenue generation, due to the high consumption and utility rates of tissue diagnostic solutions in healthcare settings. The physicians are increasingly switching to tissue-based diagnostic testing techniques from conventional testing procedures. This is because tissue diagnostic tests reduce timelines when compared to conventional methods. Hospitals are also undergoing agreement models for better disease diagnostics, thus propelling segment growth. For instance, in August 2019, the Taipei Veterans General Hospital (Taiwan) signed an agreement with Philips to install the IntelliSite Pathology Solution of the company in the hospital. This agreement helped in aiding the growth of digital pathology in tissue diagnostics.

Recent strategic developments in tissue diagnostics market

The tissue diagnostics market has undergone several significant developments, and a few of these have been mentioned below:

• In September 2022, Leica Biosystems and Indica Labs, the industry-leading provider of computational and image management software in digital pathology, announced a partnership focused on delivering compatible digital pathology workflow solutions. 
• In June 2022, Roche launched the VENTANA DP 600 high-capacity slide scanner that creates well built-resolution, digital images of stained tissue samples that in turn help to diagnose cancer and determine a patient’s outcome. This mainly empowers the digital transformation of pathology and determines personalized healthcare outcomes.

The tissue diagnostics market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Abbott Laboratories; Agilent Technologies, Inc.; BioGenex Laboratories; Danaher Corporation; F. Hoffmann-La Roche Ltd; Merck KGaA; Thermo Fisher Scientific; SAKURA FINETEK JAPAN CO. LTD.; Abcam Plc.; Cell Signaling Technology, Inc. are among the prominent players operating in the market.

Target audience for the report:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Government bodies, such as regulating authorities
• Research institutes, organizations, and consulting companies
• Academic Institutes
• Research Institutes
• Contract research Organizations
• Healthcare Settings

Scope of the report:

In this report, the market has been segmented on the basis of:

• Product:
  • Consumables
    • Antibodies
    • Kits
    • Reagents
    • Probes
  • Instruments
    • Slide-staining Systems
    • Scanners
    • Tissue-processing Systems
    • Histology & Hematology Stains
    • Cytology Stains & Bacteriology Stains
    • Other Instruments

• Technology
  • Immunohistochemistry
  • In Situ Hybridization
  • Digital Pathology & Workflow
  • Management
  • Special Staining
  • Others
• Disease:
  • Breast Cancer
  • Gastric Cancer
  • Lymphoma
  • Prostate Cancer
  • Non-small Cell Lung Cancer
  • Other Diseases
• End User:
  • Hospitals
  • Pharmaceutical Companies
  • Research Laboratories
  • Contract Research Organizations
  • Other End Users              
• Region
  • North America
    • US
    • Canada
    • Mexico
  • Europe
  • Asia Pacific (APAC)
  • Middle East & Africa
  • South & Central America

Companies profiled:

• • Agilent Technologies
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BioGenex Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Thermo Fisher Scientific
  • SAKURA FINETEK JAPAN CO. LTD.
  • Abcam Plc.
  • Cell Signaling Technology, Inc.
  • Other Market Participants